Investors Alert: Biohaven Ltd. Faces Class Action Lawsuit Over Alleged Securities Violations
LOS ANGELES — A national law firm is reminding investors about a class action lawsuit against Biohaven Ltd. for alleged violations of federal securities laws. The Schall Law Firm is urging individuals who purchased the company’s securities between March 24, 2023, and May 14, 2025, to reach out before the upcoming deadline on September 12, 2025. The lawsuit claims that Biohaven provided misleading information regarding its drug candidate, troriluzole, which is intended for treating spinocerebellar ataxia (SCA). Additionally, the firm asserts that the company’s claims about the efficacy of BHV-7000, aimed at treating bipolar disorder, … Read more